DAVID GRANOVSKY

Posts Tagged ‘world health organization’

OBESITY TREATMENT DISCOVERED THROUGH STEM CELLS

In ALL ARTICLES, SCIENCE & STEM CELLS, STEM CELLS IN THE NEWS on February 13, 2013 at 9:00 am

Fighting fat with fat: Stem cell discovery identifies potential obesity treatment

February 5, 2013—Ottawa—Ottawa scientists have discovered a trigger that turns muscle stem cells into brown fat, a form of good fat that could play a critical role in the fight against obesity. The findings from Dr. Michael Rudnicki’s lab, based at the Ottawa Hospital Research Institute, were published today in the journal Cell Metabolism.

“This discovery significantly advances our ability to harness this good fat in the battle against bad fat and all the associated health risks that come with being overweight and obese,” says Dr. Rudnicki, a senior scientist at the Ottawa Hospital Research Institute. He is also a Canada Research Chair in Molecular Genetics and professor in the Faculty of Medicine at the University of Ottawa.

Globally, obesity is the fifth leading risk for death, with an estimated 2.8 million people dying every year from the effects of being overweight or obese, according to the World Health Organization. The Public Health Agency of Canada estimates that 25% of Canadian adults are obese.

In 2007, Dr. Rudnicki led a team that was the first to prove the existence of adult skeletal muscle stem cells. In the paper published today, Dr. Rudnicki now shows (again for the first time) that these adult muscle stem cells not only have the ability to produce muscle fibres, but also to become brown fat. Brown fat is an energy-burning tissue that is important to the body’s ability to keep warm and regulate temperature. In addition, more brown fat is associated with less obesity.

Dr. Rudnicki’s lab showed that adult mice injected with an agent to reduce miR-133, called an antisense oligonucleotide or ASO, produced more brown fat, were protected from obesity and had an improved ability to process glucose. In addition, the local injection into the hind leg muscle led to increased energy production throughout the body—an effect observed after four months.

52477_web

In this picture taken with a thermographic camera after four months, the mouse treated with miR-133 ASO (on the right) is noticeably leaner. In addition, the injected hind leg (on the left in the image) is 0.8 C hotter than the control mouse.

“While we are very excited by this breakthrough, we acknowledge that it’s a first step,” says Dr. Rudnicki.

The full article, “MicroRNA-133 Controls Brown Adipose Determination in Skeletal Muscle Satellite Cells by Targeting Prdm16,” was published by Cell Metabolism online ahead of print on February 5, 2013.

Photo Credit:    Rudnicki et al., Ottawa Hospital Research Institute, published in Cell Metabolism

eurekalert.org

1 MILLION CUSTOMERS SERVED

In ALL ARTICLES, STEM CELLS IN THE NEWS, VICTORIES & SUCCESS STORIES on February 1, 2013 at 9:00 am

blood_525

1 Millionth Blood Stem Cell Transplant Marks Major Medical Milestone

The collaborative work of medical scientists and physicians across the globe has resulted in a major medical milestone: the world’s 1 millionth blood stem cell transplant, a procedure that has become a proven and essential therapy for many patients battling blood cancers like leukemia and lymphoma, as well as other critical diseases.

The Worldwide Network for Blood and Marrow Transplantation (WBMT) announced the landmark achievement today. The WBMT—a nonprofit scientific organization whose mission is promoting excellence in stem cell transplantation, stem cell donation and cellular therapy—said the 1 millionth transplant occurred in late December 2012. The finding is based on data collected by WBMT international member organizations involved in blood stem cell transplantation, which were analyzed and verified by the WBMT.

“One million transplants is a milestone that may surprise many people, because blood stem cell transplants were viewed as a rare procedure until the last decade or so,” said Dietger Niederwieser, M.D., president of the WBMT and professor of medicine in the division of hematology and medical oncology at the University Hospital of Leipzig, Germany. “But important discoveries—and the vital cooperation of many scientists and physicians around the world—have dramatically improved outcomes for patients who undergo stem cell transplantation.”

The first blood stem cell transplant was reported by Dr. E. Donnall Thomas in 1957, who received the Nobel Prize in 1990 for pioneering the use of this innovative approach to treatment of leukemia and other life-threatening diseases.

By the late 1960s, as knowledge of the requirements for matching patients with donors evolved, physicians were performing successful allogeneic transplants, using blood-forming stem cells from sibling donors (among the first in U.S., Holland and France). In 1973, the first successful transplant between two unrelated people occurred in New York, when a young boy received a transplant from a donor identified as a match through a blood bank in Denmark. In 1988, the first successful umbilical cord blood transplant was performed in Paris.

Since then, a near-exponential rise in all types of blood stem cell transplants, particularly from unrelated donors, has occurred. This is largely thanks to the willingness of now more than 20 million voluntary stem cell donors worldwide. Today, unrelated transplants are often as successful as those that use family donors.

International partners will help make this continued growth possible. Already, data from the World Marrow Donor Association (WMDA), a WBMT partner, show that nearly half of the transplants performed with unrelated donors cross an international border. International donor registries not only expand the pool of potential donors, they help advance the global science of transplantation through the exchange of information.

“It must be especially emphasized that WBMT has contributed to the advances of blood stem cell transplants in emerging countries in the Asia-Pacific region and in the other areas of the world, where the awareness to this medical procedure is sharply increasing,” said Yoshihisa Kodera, vice president of WBMT, chairman of APBMT and professor of Aichi Medical University, Japan.

The World Health Organization (WHO) has recognized transplantation as an important global task, recently recognizing the WBMT as a non-governmental organization (NGO). “Transplantation has extended the lifespan of hundreds of thousands of patients worldwide and enhanced their quality of life,” said Luc Noël, M.D., of WHO. “It has become the standard of care for many patients, and should no longer be restricted to affluent countries or individuals.”

Today, more than 70 malignant and non-malignant diseases are treated routinely with blood stem cell transplantation, providing new cures for patients around the globe. The procedure technique itself has improved considerably because of dedicated cancer centers but also because of collaboration and cooperation among scientists, clinicians, nurses and data managers, as well as the 19 international scientific societies that establish standards, collect data on the procedure and analyze outcomes. In patients with optimal conditions, disease-free survival rates are now reaching more than 90 percent.

“Worldwide, more than 50,000 patients a year are receiving transplants, in regions ranging from the Asia-Pacific to the Mid-East to Central America,” said Dennis Confer, M.D., treasurer of the WBMT and chief medical officer of the U.S.-based National Marrow Donor Program® (NMDP). “The curative potential of this therapy will only increase, thanks to the commitment and collaboration of researchers and physicians across the globe.”

BERN, Switzerland, Jan. 30, 2013 (GLOBE NEWSWIRE) – (www.globenewswire.com)

WHY IS THE USA SO DAMN BEHIND? HAVE A HEART

In STEM CELLS IN THE NEWS on April 12, 2012 at 1:31 pm

My buddy David S. is raising funds for stem cell treatment for his heart.  He is a gentleman, a poet, a musician and he always seems to get right to the meat of the subject.  David asks:

What was the method used to develop [adult stem cell] therapies all over the world in other countries? Clinical trials?

————————————————–

Excellent question!

Short answer: American medical professionals are so Ameri-centric, they throw away or ignore anything (studies, trials, etc) conducted outside the USA.

I remember a few years ago, an acquaintance of mine who was pre-med sneered at my mention of any trials conducted outside the US and then sneered at the very thought of adult stem cells doing anything.  Well, I guess I’m laughing last but I brought up the point then that his arrogance was somewhat confusing to me since the USA health system is ranked 37th in the world by the World Health Organization.  What the hell was he so proud of??

HERE’S WHAT HAPPENED…

in 2005 the first stem cell treatment facility was created in Thailand where the environment was favorable (the king’s cardio thoracic surgeon was a fan of stem cells for heart disease) and theIr methods were based on half a decade of human research preceded by years and years of animal research. I present a short list of the ‘ignored’ studies below.  Read through and you will realize:

a. by the time these studies were published, everyone in the scientifically community new the results for a year or years and

b. by the time the Bangkok facility was created, Prof Doris Taylor was already creating hearts with stem cells from scratch

c. these studies and trials, when conducted outside the US, have been all but ignored and then repeated in the US. The inevitable successful trial results 6-8 years later in the US are always accompanied by an incorrect, ignorant and infuriating news article crying: “first ever in the world!”

d.  in addition to the studies/trials below, there were also hundreds or thousands of other studies showing the safety and efficacy of adult stem cell treatments in animals and humans in other organs/parts of the body.

[While, ‘it worked there, so it will work here’ is not an accepted scientific method, at some point there is an increase in confidence when you realize: adult stem cells are in the body to repair, that’s what they do, they are safe, they fix stuff, now let’s figure out how to maximize there effects.]

For more information: https://repairstemcell.wordpress.com/heart-disease-treatment/

HEART DISEASE CLINICAL STUDIES – A BRIEF HISTORY

2002

A clinical trial led by Dr. Hans Dohmann plus six colleagues in Brazil took 21 transplant candidates and gave 14 of them bone marrow cells. The results were so spectacular that the American Heart Association accepted the paper and it was presented in 2003. Five of the seven in the control group opted in to make a total of 19 stem cell transplants. The mortality rate for transplant candidates is about 35% per year. At that rate there would be, of those 19, only 2.2 patients still alive without a transplant after five years. There were, in fact, 12 alive as of Dec. 31, 2007; more than five years down the road.

If you did not want or could not get a heart transplant (as is true of 90%+ of dying heart patients in North America) then you had to make a choice between stem cell treatment or standard Western Cardiology methodology.

Western Cardiology methodology kept 12% of patients (waiting for heart transplants) alive for five years.

Adult/repair Stem cell treatments kept 63% of patients (waiting for heart transplants) alive for five years. More than 5 times more heart transplant candidates lived for 5 years with stem cell treatments than the typical heart transplant recipient! Btw, stem cell science has made huge advancements in treating heart disease over the past seven years.

2003

Dr. Andreas Zeiher of the Goethe Institute in Frankfurt began much larger trials. As of 2007, he has overseen more ASC implants into hearts than anyone, both in and out of clinical trials and he was the first to prove that timely implant of RSC in new heart attack victims improves future mortality and morbidity – http://circ.ahajournals.org/cgi/search?journalcode=circulationaha&fulltext=zeiher

2004

Dr. Amit Patel of Pittsburgh completed two of the most successful trials ever. In Uruguay, he proved, on a group of ischemic heart failure patients, that a bypass plus cells was infinitely better than a bypass only. That same year, TheraVitae, in Israel, developed a new, powerful blood-derived stem cell and dared to treat the sickest patients no clinical trial (except Brazil) would consider.

One of the Brazilians, Dr. Perin, came to Texas, used the Brazil results to get the first ASC heart clinical trial approved by the FDA. Over a dozen such approvals were granted in the next 12-18 months.

The first-ever commercial stem cell treatment center in the world starts adult stem cell treatment of hundreds of human patients. Results are amazing and include the regrowing of cardiac muscle tissue in patients, significant increases and sometimes a doubling of ejection fractions (the % volume of blood the heart can pump out per beat), etc! Stem cells are also recognized as “smart,” going to where they were needed most, creating micro-vessel bypasses around existing blockages areas, areas that previously were blocked and in areas where stents were implanted.

2005

Dr Taylor removed all cells from rat hearts except for a thin skeleton of tissue translucent as wax paper. She then injected the scaffold with fresh Cardiac Repair Stem Cells from newborn rats. Four days later, “We could see these little areas that were beginning to beat. By eight days, we could see the whole heart beating.” The experiment, reported in the journal Nature Medicine, marked the first time scientists created a functioning heart in the lab from biological tissue.

ADULT STEM CELLS vs. HEART DISEASE – UNDENIABLE SCIENTIFIC EVIDENCE

HEART DISEASE TRIAL – 2004 to 2006 –

Clinical trial illustrates the safety and efficacy of VesCell Adult Stem Cell treatment. Accepted by the American Heart Assn in 2005-6. This trial was a key element in attaining regulatory approval for the treatment protocol that improved the lives of 300 mostly “no-option” heart patients.

BRITISH JOURNAL OF HAEMOTOLOGY – 2006

Research paper shows that peripheral blood derived stem cells can differentiate into a variety of other stem cells (angiogenic, myocardial and neural lineages) and do so in sufficient quantities to use as autologous treatment for a variety of diseases.

ANGIOGENIC CELL CLINICAL STUDY – 106 CASES – 2005 to 2008

Clinical study at Chao Phya Hospital Heart Center and Siriraj Hospital H.M. Cardiac Center clinical study shows that transcoronary injection of angiogenic cells precursors improved cardiac/left ventricular ejection fraction (LVEF), exercise capacity and quality of life with high safety profile for 70% of ischemic cardiomyopathy patients with no-option revascularization.

CARDIOMYOPATHY TRIAL – 55 CASES – 2005 to 2006

Bangkok Heart Hospital and U of Pittsburgh Medical Center/McGowan Institute for Regenerative Medicine clinical trial shows that expanded autologous blood derived stem cells utilized in intramyocardial transplantation is feasible and safe in severely ill patients with intractable heart failure in all cases of dilated cardiomyopathy (DCM) and in both first-time and “redo” ischemic cardiomyopathy (ICM) patients.

PERIPHERAL ARTERY DISEASE – SCIENTIFIC PAPER – 6 CASES

Shows the safety, and feasibility and enhancement of limb salvage from implantation of non-mobilized peripheral blood angiogenic cell precursors (NMPB-ACPs) in 80% of patients with critical limb ischemia (CLI) who were poor candidates for standard revascularization treatment options.

BIOPROCESSING JOURNAL – 2007

Bioprocessing Journal scientific paper shows the consistent and reliable manufacturing procedure utilized for transforming bone marrow and blood-derived stem cells into angiogenic cell precursors (ACPs) and hematopoietic stem cell (HSC) cellular products for the treatment of severe heart diseases. End product was found to be a) safe and effective; b) prepared from non-mobilized peripheral blood; c) stable, with a relatively long shelf-life; and d) ready-to-use and easily utilized by the physician.

%d bloggers like this: